{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:43:32Z","timestamp":1793889812280,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2021-ct06, lzujbky-2021-kb22"],"award-info":[{"award-number":["lzujbky-2021-ct06, lzujbky-2021-kb22"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched four electronic databases from database inception to August 31, 2023, to identify randomized controlled trials (RCTs) that report efficacy and safety for the acute treatment of migraine. The risk of bias in the included RCTs was evaluated according to the Cochrane tool, and the certainty of evidence using the CINeMA approach. We conducted frequentist network meta-analyses (NMA) to summarise the evidence. Data were analyzed using R-4.3.1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 18 eligible studies including 10 different types of interventions with 22,429 migraine patients were included. NMA results showed that compared to ubrogepant (25\u00a0mg and 50\u00a0mg) and zavegepant, lasmiditan (100\u00a0mg and 200\u00a0mg) exhibits an elevated probability of achieving pain relief within a 2-hour interval. Similarly, relative to zavegepant, rimegepant (75\u00a0mg) and ubrogepant (50\u00a0mg and 100\u00a0mg) demonstrate an enhanced likelihood of sustaining pain relief over a 24-hour period. Furthermore, in contrast to ubrogepant (25\u00a0mg) and lasmiditan (50\u00a0mg), rimegepant (75\u00a0mg) presents a heightened probability of achieving freedom from photophobia within 2\u00a0h. Regarding safety, lasmiditan carries the highest risk of adverse events, which are associated with an increased incidence of adverse effects, including dizziness, somnolence, asthenia, paresthesia, and fatigue.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this NMA, a spectrum of evidence ranging from very low to high levels underscores the favorable efficacy and tolerability of rimegepant 75\u00a0mg and ubrogepant 100\u00a0mg, positioning them as potential candidates for the acute management of migraine. Concurrently, lasmiditan (100\u00a0mg and 200\u00a0mg) exhibits notable efficacy, albeit accompanied by an increased susceptibility to adverse events. These findings should still be approached with caution, primarily due to the intrinsic limitations associated with indirect comparisons.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01723-4","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:02:41Z","timestamp":1707091361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Xinxin","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangle","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"issue":"4","key":"1723_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/s1474-4422(08)70062-0","volume":"7","author":"R Jensen","year":"2008","unstructured":"Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. Lancet Neurol 7(4):354\u2013361. https:\/\/doi.org\/10.1016\/s1474-4422(08)70062-0","journal-title":"Lancet Neurol"},{"issue":"9","key":"1723_CR2","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40263-022-00948-8","volume":"36","author":"N Karsan","year":"2022","unstructured":"Karsan N, Goadsby PJ (2022) New oral drugs for migraine. CNS Drugs 36(9):933\u2013949. https:\/\/doi.org\/10.1007\/s40263-022-00948-8","journal-title":"CNS Drugs"},{"issue":"1","key":"1723_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"11","key":"1723_CR4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1177\/0333102414566200","volume":"35","author":"YW Woldeamanuel","year":"2015","unstructured":"Woldeamanuel YW, Rapoport AM, Cowan RP (2015) The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia 35(11):996\u20131024. https:\/\/doi.org\/10.1177\/0333102414566200","journal-title":"Cephalalgia"},{"issue":"5","key":"1723_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC et al (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13(5):361\u2013378. https:\/\/doi.org\/10.1007\/s10194-012-0460-7","journal-title":"J Headache Pain"},{"key":"1723_CR6","doi-asserted-by":"publisher","unstructured":"The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice (2019) Headache 59(1):1\u201318. https:\/\/doi.org\/10.1111\/head.13456","DOI":"10.1111\/head.13456"},{"issue":"Suppl 1","key":"1723_CR7","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1526-4610.2004.04105.x","volume":"44","author":"DW Dodick","year":"2004","unstructured":"Dodick DW, Martin VT, Smith T, Silberstein S (2004) Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 44(Suppl 1):S20-30. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04105.x","journal-title":"Headache"},{"issue":"12","key":"1723_CR8","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","volume":"37","author":"E Leroux","year":"2020","unstructured":"Leroux E, Buchanan A, Lombard L et al (2020) Evaluation of patients with Insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther 37(12):4765\u20134796. https:\/\/doi.org\/10.1007\/s12325-020-01494-9","journal-title":"Adv Ther"},{"key":"1723_CR9","unstructured":"Food and Drug Administration (2019) FDA approves new treatment for patients with migraine, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-patients-migraine . Accessed 13 Mar 2022"},{"issue":"7","key":"1723_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","volume":"177","author":"L Edvinsson","year":"2021","unstructured":"Edvinsson L (2021) CGRP and migraine: from bench to bedside. Rev Neurol (Paris) 177(7):785\u2013790. https:\/\/doi.org\/10.1016\/j.neurol.2021.06.003","journal-title":"Rev Neurol (Paris)"},{"key":"1723_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume":"255","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L (2019) Role of CGRP in migraine. Handb Exp Pharmacol 255:121\u2013130. https:\/\/doi.org\/10.1007\/164_2018_201","journal-title":"Handb Exp Pharmacol"},{"key":"1723_CR12","doi-asserted-by":"publisher","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther Jul 211:107528. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","journal-title":"Pharmacol Ther Jul"},{"issue":"7","key":"1723_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Rimegepant: first approval. Drugs 80(7):741\u2013746. https:\/\/doi.org\/10.1007\/s40265-020-01301-3","journal-title":"Drugs"},{"issue":"3","key":"1723_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Ubrogepant: first approval. Drugs 80(3):323\u2013328. https:\/\/doi.org\/10.1007\/s40265-020-01264-5","journal-title":"Drugs"},{"issue":"7","key":"1723_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14656566.2020.1721462","volume":"21","author":"M Curto","year":"2020","unstructured":"Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L (2020) Ubrogepant for the treatment of migraine. Expert Opin Pharmacother 21(7):755\u2013759. https:\/\/doi.org\/10.1080\/14656566.2020.1721462","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"1723_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S (2023) Zavegepant: first approval. Drugs 83(9):825\u2013831. https:\/\/doi.org\/10.1007\/s40265-023-01885-6","journal-title":"Drugs"},{"issue":"5","key":"1723_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M (2021) Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61(5):755\u2013765. https:\/\/doi.org\/10.1111\/head.14122","journal-title":"Headache"},{"issue":"3","key":"1723_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40120-022-00369-1","volume":"11","author":"T Yu","year":"2022","unstructured":"Yu T, He L, Yang X et al (2022) Efficacy and safety of lasmiditan as a novel acute treatment in Chinese patients with migraine: a subpopulation analysis of the randomized controlled phase 3 CENTURION trial. Neurol Ther 11(3):1269\u20131283. https:\/\/doi.org\/10.1007\/s40120-022-00369-1","journal-title":"Neurol Ther"},{"issue":"6","key":"1723_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22(6):476\u2013484. https:\/\/doi.org\/10.1016\/S1474-4422(23)00126-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"1723_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"11","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for Migraine. Article. New Engl J Med 11(2):142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"New Engl J Med"},{"issue":"17","key":"1723_CR21","doi-asserted-by":"publisher","first-page":"e1905","DOI":"10.1212\/wnl.0000000000201031","volume":"25","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Dodick DW, Goadsby PJ et al (2022) Efficacy of ubrogepant in the acute treatment of migraine with mild pain vs moderate or severe pain. Neurology 25(17):e1905\u2013e1915. https:\/\/doi.org\/10.1212\/wnl.0000000000201031","journal-title":"Neurology"},{"issue":"9","key":"1723_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R, Madonia J, Stock DA et al (2022) Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62(9):1153\u20131163. https:\/\/doi.org\/10.1111\/head.14389","journal-title":"Headache"},{"issue":"3","key":"1723_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial randomized controlled trial; multicenter study; clinical trial, Phase III; research support, non-US Gov\u2019t. Lancet Neurol 22(3):209\u2013217. https:\/\/doi.org\/10.1016\/s1474-4422(22)00517-8","journal-title":"Lancet Neurol"},{"issue":"11","key":"1723_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"2","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2(11):777\u2013784. https:\/\/doi.org\/10.7326\/m14-2385","journal-title":"Ann Intern Med"},{"key":"1723_CR25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"2","key":"1723_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3(2):111\u2013125. https:\/\/doi.org\/10.1002\/jrsm.1045","journal-title":"Res Synth Methods"},{"issue":"10","key":"1723_CR27","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G (2013) Graphical tools for network meta-analysis in STATA. PLoS One 8(10):e76654. https:\/\/doi.org\/10.1371\/journal.pone.0076654","journal-title":"PLoS One"},{"issue":"25","key":"1723_CR28","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","volume":"10","author":"G R\u00fccker","year":"2014","unstructured":"R\u00fccker G, Schwarzer G (2014) Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. Stat Med 10(25):4353\u20134369. https:\/\/doi.org\/10.1002\/sim.6236","journal-title":"Stat Med"},{"key":"1723_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2021.09.014","volume":"141","author":"X Li","year":"2022","unstructured":"Li X, Li Y, Guo K et al (2022) Evidence based social science in China paper 3: the quality of social science RCTs published from 2000\u20132020. J Clin Epidemiol 141:64\u201373. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.09.014","journal-title":"J Clin Epidemiol"},{"key":"1723_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"9","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J (2013) A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 9:35. https:\/\/doi.org\/10.1186\/1471-2288-13-35","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"1723_CR31","doi-asserted-by":"publisher","first-page":"e13303","DOI":"10.1111\/adb.13303","volume":"28","author":"X Deng","year":"2023","unstructured":"Deng X, Shang X, Guo K et al (2023) Efficacy and safety of antidepressants for smoking cessation: a systematic review and network meta-analysis. Addict Biol 28(8):e13303. https:\/\/doi.org\/10.1111\/adb.13303","journal-title":"Addict Biol"},{"issue":"4","key":"1723_CR32","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al (2020) CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082","journal-title":"PLoS Med"},{"key":"1723_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jclinepi.2016.01.003","volume":"74","author":"L Yao","year":"2016","unstructured":"Yao L, Sun R, Chen YL et al (2016) The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol 74:73\u201379. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.003","journal-title":"J Clin Epidemiol"},{"key":"1723_CR34","doi-asserted-by":"publisher","first-page":"101577","DOI":"10.3389\/fphar.2019.01577","volume":"24","author":"B Gao","year":"2020","unstructured":"Gao B, Yang Y, Wang Z et al (2020) Efficacy and safety of Rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Review. Front Pharmacol 24:101577. https:\/\/doi.org\/10.3389\/fphar.2019.01577","journal-title":"Front Pharmacol"},{"issue":"1","key":"1723_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","volume":"5","author":"M Hou","year":"2020","unstructured":"Hou M, Xing H, Li C et al (2020) Short-term efficacy and safety of lasmiditan, a novel 5-HT(1F) receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain 5(1):66. https:\/\/doi.org\/10.1186\/s10194-020-01138-x","journal-title":"J Headache Pain"},{"issue":"8","key":"1723_CR36","doi-asserted-by":"publisher","first-page":"e24741","DOI":"10.1097\/md.0000000000024741","volume":"26","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Shu Y, Diao Y et al (2021) Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: a meta-analysis. Med (Baltimore) 26(8):e24741. https:\/\/doi.org\/10.1097\/md.0000000000024741","journal-title":"Med (Baltimore)"},{"issue":"1","key":"1723_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-022-01440-w","volume":"6","author":"P Polavieja","year":"2022","unstructured":"Polavieja P, Belger M, Venkata SK, Wilhelm S, Johansson E (2022) Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings. J Headache Pain 6(1):76. https:\/\/doi.org\/10.1186\/s10194-022-01440-w","journal-title":"J Headache Pain"},{"issue":"3","key":"1723_CR38","doi-asserted-by":"publisher","first-page":"333102423115141","DOI":"10.1177\/03331024231151419","volume":"43","author":"F Puledda","year":"2023","unstructured":"Puledda F, Younis S, Huessler EM et al (2023) Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia 43(3):3331024231151419. https:\/\/doi.org\/10.1177\/03331024231151419","journal-title":"Cephalalgia"},{"issue":"1","key":"1723_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14737167.2021.1945444","volume":"22","author":"K Johnston","year":"2022","unstructured":"Johnston K, Popoff E, Deighton A et al (2022) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Article. Expert Rev Pharmacoeconomics Outcomes Res 22(1):155\u2013166. https:\/\/doi.org\/10.1080\/14737167.2021.1945444","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"10","key":"1723_CR40","doi-asserted-by":"publisher","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"1","author":"CP Yang","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 1(10):e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544","journal-title":"JAMA Netw Open"},{"key":"1723_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00795","volume":"10","author":"F Xu","year":"2019","unstructured":"Xu F, Sun W (2019) Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol 10:795. https:\/\/doi.org\/10.3389\/fphar.2019.00795","journal-title":"Front Pharmacol"},{"issue":"7","key":"1723_CR42","doi-asserted-by":"publisher","first-page":"e41991","DOI":"10.7759\/cureus.41991","volume":"15","author":"ZZ Khan","year":"2023","unstructured":"Khan ZZ, Ahmed U, Shahzad F et al (2023) Safety and efficacy of Zavegepant in treating migraine: a systematic review. Cureus 15(7):e41991. https:\/\/doi.org\/10.7759\/cureus.41991","journal-title":"Cureus"},{"key":"1723_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jclinepi.2021.02.021","volume":"135","author":"Y Li","year":"2021","unstructured":"Li Y, Cao L, Zhang Z et al (2021) Reporting and methodological quality of COVID-19 systematic reviews needs to be improved: an evidence mapping. J Clin Epidemiol 135:17\u201328. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.02.021","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1723_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.zefq.2012.10.018","volume":"106","author":"M Perleth","year":"2012","unstructured":"Perleth M, Langer G, Meerpohl JJ, Gartlehner G, Kaminski-Hartenthaler A, Sch\u00fcnemann HJ (2012) GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Z Evid Fortbild Qual Gesundhwes 106(10):733\u2013744. https:\/\/doi.org\/10.1016\/j.zefq.2012.10.018. (GRADE Leitlinien: 7. Einsch\u00e4tzung der Qualit\u00e4t der Evidenz - Inkonsistenz)","journal-title":"Z Evid Fortbild Qual Gesundhwes"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01723-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01723-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:03:02Z","timestamp":1707091382000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01723-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1723"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01723-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}